{"id":"https://openalex.org/W2586466848","doi":"https://doi.org/10.1182/blood.v128.22.1217.1217","title":"Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study","display_name":"Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2586466848","doi":"https://doi.org/10.1182/blood.v128.22.1217.1217","mag":"2586466848"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.1217.1217","doi":"https://doi.org/10.1182/blood.v128.22.1217.1217","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.1217.1217","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I1332479046","display_name":"Seattle Cancer Care Alliance","ror":"https://ror.org/03jq88n71","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1332479046"]},{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":["Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I1332479046","https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080630441","display_name":"Stephen J. Schuster","orcid":"https://orcid.org/0000-0002-3376-8978","observed_orcids":["https://orcid.org/0000-0002-3376-8978"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen J. Schuster","raw_affiliation_strings":["Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044284041","display_name":"Nathan Hale Fowler","orcid":"https://orcid.org/0000-0002-9494-1877","observed_orcids":["https://orcid.org/0000-0002-9494-1877"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan Fowler","raw_affiliation_strings":["Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082805908","display_name":"Judith Trotman","orcid":"https://orcid.org/0000-0001-8009-4593","observed_orcids":["https://orcid.org/0000-0001-8009-4593"]},"institutions":[{"id":"https://openalex.org/I2800249840","display_name":"Concord Repatriation General Hospital","ror":"https://ror.org/04b0n4406","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800249840"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Judith Trotman","raw_affiliation_strings":["Concord Hospital, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Concord Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I2800249840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011863718","display_name":"Georg He\u00df","orcid":"https://orcid.org/0000-0002-9282-5688","observed_orcids":["https://orcid.org/0000-0002-9282-5688"]},"institutions":[{"id":"https://openalex.org/I197323543","display_name":"Johannes Gutenberg University Mainz","ror":"https://ror.org/023b0x485","country_code":"DE","type":"education","lineage":["https://openalex.org/I197323543"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Georg Hess","raw_affiliation_strings":["Department of Hematology/Oncology, Johannes Gutenberg University, Langenbeckstr, Mainz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology/Oncology, Johannes Gutenberg University, Langenbeckstr, Mainz, Germany","institution_ids":["https://openalex.org/I197323543"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001718295","display_name":"Jing\u2010Zhou Hou","orcid":"https://orcid.org/0000-0001-8916-0921","observed_orcids":["https://orcid.org/0000-0001-8916-0921"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing-Zhou Hou","raw_affiliation_strings":["University of Pittsburgh Medical Center, UPMC CancerCenter, University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Medical Center, UPMC CancerCenter, University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071257161","display_name":"Abdulraheem Yacoub","orcid":"https://orcid.org/0000-0001-5293-4620","observed_orcids":["https://orcid.org/0000-0001-5293-4620"]},"institutions":[{"id":"https://openalex.org/I146416000","display_name":"University of Kansas","ror":"https://ror.org/001tmjg57","country_code":"US","type":"education","lineage":["https://openalex.org/I146416000"]},{"id":"https://openalex.org/I2802196186","display_name":"The University of Kansas Health System","ror":"https://ror.org/05kg11974","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802196186"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdulraheem Yacoub","raw_affiliation_strings":["University of Kansas Medical Hospital, Westwood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kansas Medical Hospital, Westwood, KS","institution_ids":["https://openalex.org/I146416000","https://openalex.org/I2802196186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001921808","display_name":"Michael Lill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Lill","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040141808","display_name":"Peter Martin","orcid":"https://orcid.org/0000-0001-7813-1551","observed_orcids":["https://orcid.org/0000-0001-7813-1551"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Martin","raw_affiliation_strings":["Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000403848","display_name":"Umberto Vitolo","orcid":"https://orcid.org/0000-0001-7772-2747","observed_orcids":["https://orcid.org/0000-0001-7772-2747"]},"institutions":[{"id":"https://openalex.org/I4210086903","display_name":"Azienda Ospedaliera Citta' della Salute e della Scienza di Torino","ror":"https://ror.org/001f7a930","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210086903"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Umberto Vitolo","raw_affiliation_strings":["SC Ematologia, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza, Torino, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SC Ematologia, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza, Torino, Italy","institution_ids":["https://openalex.org/I4210086903"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I126596746","display_name":"Jagiellonian University","ror":"https://ror.org/03bqmcz70","country_code":"PL","type":"education","lineage":["https://openalex.org/I126596746"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["Department of Hematology, Jagiellonian University, Krakow, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Jagiellonian University, Krakow, Poland","institution_ids":["https://openalex.org/I126596746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113491786","display_name":"James Morton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210167184","display_name":"Icon (Australia)","ror":"https://ror.org/05nh0hr31","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210167184"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"James Morton","raw_affiliation_strings":["Icon Cancer Care, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Icon Cancer Care, Brisbane, Australia","institution_ids":["https://openalex.org/I4210167184"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013551807","display_name":"\u041e\u0441\u043c\u0430\u043d\u043e\u0432 \u0414\u0436\u0435\u043b\u0438\u043b \u0428\u0435\u0432\u043a\u0435\u0442\u043e\u0432\u0438\u0447","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090957","display_name":"Russian Cancer Research Center NN Blokhin","ror":"https://ror.org/00ab9fg88","country_code":"RU","type":"facility","lineage":["https://openalex.org/I4210090957"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Dzhelil Osmanov","raw_affiliation_strings":["Blokhin Cancer Research Center under the Russian Academy of Medical Sciences, Moscow, Russian Federation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blokhin Cancer Research Center under the Russian Academy of Medical Sciences, Moscow, Russian Federation","institution_ids":["https://openalex.org/I4210090957"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082184204","display_name":"Gary J. Gartenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary J. Gartenberg","raw_affiliation_strings":["Janssen Research & Development, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, NJ","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053469869","display_name":"JESSICA T. VERMEULEN","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154236","display_name":"Janssen (Netherlands)","ror":"https://ror.org/04cxegr21","country_code":"NL","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210154236"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Jessica Vermeulen","raw_affiliation_strings":["Janssen Research & Development, Leiden, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Leiden, Netherlands","institution_ids":["https://openalex.org/I4210154236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079048180","display_name":"Sriram Balasubramanian","orcid":"https://orcid.org/0000-0003-2018-2094","observed_orcids":["https://orcid.org/0000-0003-2018-2094"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sriram Balasubramanian","raw_affiliation_strings":["Janssen Research & Development, Springhouse, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Springhouse, PA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079135461","display_name":"Shean\u2010Sheng Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shean-sheng Wang","raw_affiliation_strings":["Janssen Research & Development, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, NJ","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sanjay Deshpande","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay Deshpande","raw_affiliation_strings":["Janssen Research & Development, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, NJ","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles A. Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I4210113288","display_name":"H\u00f4pital Lyon Sud","ror":"https://ror.org/023xgd207","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100596","https://openalex.org/I4210113288"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Gilles A. Salles","raw_affiliation_strings":["Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre Benite, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre Benite, France","institution_ids":["https://openalex.org/I4210113288"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":21,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":2.0758,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.88073444,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"128","issue":"22","first_page":"1217","last_page":"1217"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.5981000065803528,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.5981000065803528,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.40059998631477356,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9269999861717224},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.8479999899864197},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7059999704360962},{"id":"https://openalex.org/keywords/itk-inhibitors","display_name":"ITK inhibitors","score":0.6959999799728394},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.8989999890327454},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7749999761581421},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9459999799728394},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8090000152587891},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6190000176429749},{"id":"https://openalex.org/keywords/tumor-flare","display_name":"tumor flare","score":0.4339999854564667},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.38600000739097595}],"concepts":[{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.9372972249984741},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.9369503259658813},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7855339050292969},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.573707103729248},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5230984687805176},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.5151735544204712},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.5151668787002563},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.49262291193008423},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.44864118099212646},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42805781960487366},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.41375473141670227},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.3782673180103302},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.34954833984375},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.33311647176742554},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.2578554153442383},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.24238666892051697},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.232840895652771},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.18185043334960938},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0946921706199646},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.1217.1217","doi":"https://doi.org/10.1182/blood.v128.22.1217.1217","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.1217.1217","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2806493073","https://openalex.org/W2523635755","https://openalex.org/W2557010481","https://openalex.org/W2622107576","https://openalex.org/W2619293667","https://openalex.org/W2588151162","https://openalex.org/W2951735615","https://openalex.org/W2558467416","https://openalex.org/W4236401988","https://openalex.org/W2902775612"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"While":[2],"first":[3],"line":[4,415],"therapy":[5,138],"for":[6,192,369,558,582],"FL":[7,19,74,106,128,573,624],"with":[8,18,65,70,100,126,139,183,327,351,409,524,566,571,605,622,631,638],"chemotherapy":[9,151],"or":[10,72,173,560,701,808,823],"chemoimmunotherapy":[11,27,154],"produces":[12],"durable":[13,575],"responses,":[14],"most":[15,482],"patients":[16,182],"(pts)":[17],"eventually":[20],"relapse.":[21],"Those":[22],"who":[23,340,444,469,625],"become":[24],"resistant":[25],"to":[26,93,186,190,229,281,286,380,397,419,543,552],"have":[28,61,626],"limited":[29,627],"treatment":[30,231,417,628,630],"options.":[31],"Ibrutinib,":[32],"an":[33,115,157,539,696,803,818],"inhibitor":[34],"of":[35,88,122,137,150,195,225,240,267,273,331,333,336,416,451,475,515,538,577,593,610,614,699,806,821],"BTK":[36],"(Bruton's":[37],"tyrosine":[38],"kinase)":[39],"and":[40,58,97,198,243,296,321,466,502,519,529,596,641,842],"ITK":[41],"(interleukin-2-inducible":[42],"T-cell":[43],"kinase),":[44],"has":[45,429],"demonstrated":[46],"robust":[47],"clinical":[48,580,636],"activity":[49],"in":[50,68,103,124,152,256,349,455,513,569,600,634],"various":[51],"B-cell":[52],"non-Hodgkin":[53],"lymphomas.":[54],"Previous":[55],"Phase":[56,119],"1":[57,545],"2":[59,120,134],"studies":[60],"shown":[62],"promising":[63],"results":[64,599],"single-agent":[66,101,567],"ibrutinib":[67,102,123,167,189,299,308,383,404,536,568,632],"pts":[69,125,131,162,251,274,339,350,377,391,443,457,468,491,498,533,570,584,621],"relapsed":[71],"refractory":[73,276,344],"(Bartlett":[75],"NL.":[76],"Blood.":[77,83],"2014;":[78],"800":[79],"&":[80,706,860,865,870,875,880],"Fowler":[81],"N.":[82],"2015;":[84],"2706).":[85],"The":[86,110,201,246,259,305,314,358,426,472,481,579],"aim":[87],"the":[89,193,287,337,413,433,606,612],"DAWN":[90,111],"study":[91,112,121,602],"was":[92,114,204,262,270,301,310,318,324,347,373,405,423,436,453,464,478],"provide":[94],"additional":[95],"efficacy":[96],"safety":[98,640],"data":[99],"a":[104,153,328,548,635],"chemoimmunotherapy-refractory":[105,127,572,623],"pt":[107,546],"population.":[108],"Methods:":[109],"(FLR2002)":[113],"open-label,":[116],"multicenter,":[117],"single-arm,":[118],"(NCT01779791).":[129],"Eligible":[130],"had":[132,275,343,392,445,470,492,499],"\u2265":[133,370],"prior":[135,268,289,418],"lines":[136],"documented":[140],"progressive":[141],"disease":[142,171,277,353,359,367,589],"(PD)":[143],"within":[144],"12":[145],"months":[146,295,407,411],"after":[147,384],"last":[148,288,414],"dose":[149,549],"regimen":[155],"comprising":[156],"anti-CD20":[158],"monoclonal":[159],"antibody.":[160],"All":[161],"received":[163],"560":[164],"mg":[165],"oral":[166],"once":[168],"daily":[169],"until":[170],"progression":[172,561],"unacceptable":[174],"toxicity.":[175],"A":[176],"protocol":[177],"amendment":[178],"allowed":[179,379,396],"clinically":[180],"stable":[181,366],"radiographic":[184,386],"PD":[185,387],"remain":[187,381,398],"on":[188,382,399,403,412,695,802,817],"allow":[191],"possibility":[194],"tumor":[196],"flare":[197],"delayed":[199],"responses.":[200],"primary":[202],"objective":[203,209],"Independent":[205],"Review":[206],"Committee":[207],"(IRC)-assessed":[208],"response":[210,214,218,226,332,394,463,559],"rate":[211,323,361],"(ORR;":[212],"complete":[213],"[CR]":[215],"+":[216,363,365],"partial":[217],"[PR]).":[219],"Secondary/":[220],"exploratory":[221],"objectives":[222],"included":[223,249],"duration":[224,330,474],"(DoR),":[227],"time":[228],"next":[230],"(TTNT),":[232],"progression-free":[233],"survival":[234,237],"(PFS),":[235],"overall":[236],"(OS),":[238],"resolution":[239,450,477,592],"lymphoma-related":[241,446],"symptoms,":[242,594],"safety.":[244],"Results:":[245],"final":[247],"analysis":[248],"110":[250],"enrolled":[252],"at":[253,283,448,527],"45":[254],"centers":[255],"10":[257,410,460],"countries.":[258],"median":[260,265,297,329,427,473],"age":[261],"61.5":[263],"years,":[264],"number":[266],"therapies":[269],"3;":[271],"40.9%":[272],"(defined":[278],"as":[279],"failure":[280],"achieve":[282],"least":[284],"PR":[285,364],"regimen).":[290],"Median":[291,401,421],"follow-up":[292],"is":[293,585],"27.7":[294],"(range)":[298],"exposure":[300,309],"7.0":[302],"(1-37)":[303],"months.":[304,313,425,480],"mean":[306],"(SD)":[307],"11.2":[311],"(9.9)":[312],"ORR":[315,346],"by":[316,588],"IRC":[317],"20.9%":[319],"(23/110)":[320],"CR":[322],"10.9%":[325],"(12/110)":[326],"19.4":[334],"months;":[335],"23":[338],"responded,":[341],"5":[342],"disease.":[345],"24.7%":[348],"non-bulky":[352],"(longest":[354],"diameter":[355],"\u22646":[356],"cm).":[357],"control":[360,590],"(CR":[362],"[SD":[368],"6":[371],"months])":[372],"56.3%":[374],"(62/110).":[375],"30":[376],"were":[378,487,506,511,522,603,617],"initial":[385],"(termed":[388],"pseudo-progression);":[389],"7":[390],"IRC-confirmed":[393],"when":[395],"therapy.":[400],"TTNT":[402,595],"16":[406],"compared":[408],"enrollment.":[420],"PFS":[422],"4.6":[424],"OS":[428,435],"not":[430],"been":[431],"reached;":[432],"24-month":[434],"63%":[437],"(95%":[438],"CI,":[439],"0.53-0.72).":[440],"Of":[441],"39":[442],"symptoms":[447,452],"baseline,":[449],"seen":[454],"26":[456],"(66.7%),":[458],"including":[459],"whose":[461],"best":[462],"SD":[465],"8":[467],"PD.":[471],"symptom":[476],"10.4":[479],"common":[483],"adverse":[484],"events":[485,615],"(AEs)":[486],"diarrhea":[488],"(50.9%;":[489],"51/56":[490],"grade":[493,500,507,618],"1/2),":[494,501],"fatigue":[495],"(40.0%;":[496],"38/44":[497],"cough":[503],"(35.5%;":[504],"all":[505],"1/2).":[508],"Serious":[509],"AEs":[510],"reported":[512,616],"48.2%":[514],"pts.":[516],"Major":[517],"hemorrhage":[518],"atrial":[520],"fibrillation":[521],"consistent":[523,604],"previous":[525],"reports":[526],"3.6%":[528],"9.1%,":[530],"respectively.":[531],"Seven":[532],"(6.4%)":[534],"discontinued":[535],"because":[537],"AE":[540],"(none":[541],"due":[542,551],"AF);":[544],"required":[547],"reduction":[550],"AE.":[553],"Biomarker":[554],"analyses":[555],"identifying":[556],"classifiers":[557],"are":[562],"ongoing.":[563],"Conclusion:":[564],"Treatment":[565],"achieved":[574],"responses":[576],"20.9%.":[578],"benefit":[581,637],"these":[583],"also":[586],"supported":[587],"rate,":[591],"OS.":[597],"Safety":[598],"this":[601],"current":[607],"known":[608],"profile":[609],"ibrutinib;":[611],"majority":[613],"1/2.":[619],"In":[620],"options,":[629],"resulted":[633],"acceptable":[639],"good":[642],"tolerability.":[643],"Figure":[644,646,648,650],"1.":[645,647],"2.":[649,651],"Disclosures":[652],"Gopal:":[653],"Paid":[654],"Consultancy-":[655],"Gilead,":[656,663],"Janssen,":[657,664,835],"Seattle":[658,671,763],"Genetics,":[659],"Spectrum,":[660,670],"Research":[661,675,680,683,688,705,708,712,718,721,725,732,736,739,743,753,777,844,856,859,864,869,874,879,890,904],"funding-":[662],"Pfizer,":[665,751,832],"BMS,":[666],"Merck,":[667],"Teva,":[668,841],"Takeda,":[669,839],"Genetics:":[672,764],"Consultancy,":[673,678,686,692,711,715,724,731,735,742,765,770,780,783,791,884,893,896,899,902],"Honoraria,":[674,679,687,693,766,771,792,800,889,903],"Funding.":[676,722,744,857,905],"Schuster:Celgene:":[677],"Funding;":[681,684,689,709,713,719,726,733,737,740,754,778,845,891],"Gilead:":[682,738,782,813,888],"Novartis:":[685,759,895],"Nordic":[690],"Nanovector:":[691],"Membership":[694,801,816],"entity's":[697,804,819],"Board":[698,805,820],"Directors":[700,807,822],"advisory":[702,809,824],"committees;":[703,810],"Janssen":[704],"Development:":[707,861,866,871,876,881],"Pharmacyclics:":[710],"Genentech:":[714],"Honoraria;":[716,746,748,756,758,762,781,798,812,814,885,887,894,897,900],"Hoffman-LaRoche:":[717],"Merck:":[720],"Fowler:Roche:":[723],"TG":[727],"Therapeutics:":[728],"Consultancy;":[729,775,789,829],"Infinity:":[730],"Jannsen:":[734],"Celgene:":[741,747,752,779],"Hess:Roche:":[745],"Roche,":[749],"CTI,":[750],"Janssen:":[755,790,799,898],"Pfizer:":[757],"Honoraria.":[760],"Yacoub:Alexion:":[761],"Speakers":[767,772,826,851],"Bureau;":[768],"Incyte:":[769],"Bureau.":[773,827,852],"Martin:Novartis:":[774],"Teva:":[776],"Other:":[784,793],"travel,":[785,794],"accommodations,":[786,795],"expenses;":[787],"Acerta:":[788],"expenses.":[796],"Vitolo:Celgene:":[797],"Takeda:":[811],"Roche:":[815,843,850],"committees,":[825],"Jurczak:Morphosys:":[828],"Acerta,":[830],"Novartis,":[831,848],"Celgene,":[833],"Gillead,":[834],"Celtrion,":[836],"Bayer,":[837],"Morphosys,":[838,849],"Servier,":[840],"Sandoz":[846],"-":[847],"Osmanov:Seattle":[853],"Genetics":[854],"Inc.:":[855],"Gartenberg:Janssen":[858],"Employment.":[862,867,872,877,882],"Vermeulen:Janssen":[863],"Balasubramanian:Janssen":[868],"Wang:Janssen":[873],"Deshpande:Janssen":[878],"Salles:Celgene:":[883],"Mundipharma:":[886],"Amgen:":[892],"Roche/Genentech:":[901]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2017-02-17T00:00:00"}